Rather than open access or blanket exclusions, leading employers are tying GLP-1 coverage to objective clinical criteria: BMI thresholds, documented comorbidities, and biometric screening data
Therapies based on glucagon-like peptide-1 (GLP-1) reduce rates of cardiovascular and chronic kidney disease in people with type 2 diabetes and/or obesity, with ongoing clinical trials investigating their effects in people with metabolic liver disease, arthritis, and both substance use and neurodegenerative disorders
Semaglutide is generally considered safe for people with type 2 diabetes or those needing weight loss, but there is no specific research on its safety in people with fibromyalgia
Clinical studies help clarify the connection: In simple terms: the trigger is the speed of weight loss, not tirzepatide itself
Recognizing Dangerous Symptoms of Semaglutide Overdose The most common sign of excessive semaglutide exposure is severe, intractable nausea lasting hours and accompanied by vomiting or diarrhea that doesn't respond to anti-nausea medication
Zhu LQ, Wang SH, Ling ZQ, Wang DL, Wang JZ